Nephrology

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.

Today, nearly 37 million Americans have chronic kidney disease (CKD), yet only about one percent of those Americans are even aware of their disease. And access to care is under threat.

Your daily dose of the clinical news you may have missed.

In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

Your daily dose of the clinical news you may have missed.

Findings from the large meta-analysis provide strong support for use of both classes to reduce CV and renal disease in adults with type 2 diabetes.

Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.

Your daily dose of the clinical news you may have missed.

The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.

The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The overall CKD population will reach 125 million by 2032 across 8 industrialized nations, with significant clinical, social, economic, and environmental costs.

New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.

ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.

Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.

Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.

The KDIGO 2024 CKD Practice Guideline is the first update since the 2012 iteration and so is based on the newest research on treatment and technology available.

Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.

The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Adults who said they always added extra salt to their food had an 11% higher risk for developing CKD compared with those who never or only rarely added salt, according to new research.

Findings underscore the importance of preventive measures and management of risk factors associated with CKD in adolescents with elevated BMI, report researchers.

Your daily dose of the clinical news you may have missed.